FDA Lifts Clinical Hold On PharmAthene's SparVax Anthrax Vaccine

The U.S. Food and Drug Administration has lifted the clinical hold previously placed on a proposed Phase II study of SparVax, a next generation recombinant anthrax vaccine, PharmAthene, Inc.

http://www.science20.com/news_articles/fda_lifts_clinical_hold_pharmathenes_sparvax_anthrax_vaccine-113590